Compare FENG & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FENG | CLGN |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Broadcasting | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 18.4M |
| IPO Year | 2011 | 2015 |
| Metric | FENG | CLGN |
|---|---|---|
| Price | $1.83 | $0.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 9.4K | ★ 33.0K |
| Earning Date | 03-10-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,596.12 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $0.50 |
| 52 Week High | $3.65 | $4.98 |
| Indicator | FENG | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 43.97 |
| Support Level | $1.72 | $0.58 |
| Resistance Level | $1.87 | $0.73 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 47.83 | 24.26 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.